178 related articles for article (PubMed ID: 30342913)
1. Cytomegalovirus Infection Incidence and Risk Factors Across Diverse Hematopoietic Cell Transplantation Platforms Using a Standardized Monitoring and Treatment Approach: A Comprehensive Evaluation from a Single Institution.
Melendez-Munoz R; Marchalik R; Jerussi T; Dimitrova D; Nussenblatt V; Beri A; Rai K; Wilder JS; Barrett AJ; Battiwalla M; Childs RW; Fitzhugh CD; Fowler DH; Fry TJ; Gress RE; Hsieh MM; Ito S; Kang EM; Pavletic SZ; Shah NN; Tisdale JF; Gea-Banacloche J; Kanakry CG; Kanakry JA
Biol Blood Marrow Transplant; 2019 Mar; 25(3):577-586. PubMed ID: 30342913
[TBL] [Abstract][Full Text] [Related]
2. Differences of cytomegalovirus diseases between kidney and hematopoietic stem cell transplant recipients during preemptive therapy.
Kim T; Lee YM; Lee SO; Choi SH; Kim YS; Woo JH; Sung H; Jung JH; Shin S; Kim YH; Kang YA; Lee YS; Lee JH; Lee JH; Lee KH; Park SK; Han DJ; Kim SH
Korean J Intern Med; 2016 Sep; 31(5):961-70. PubMed ID: 27055664
[TBL] [Abstract][Full Text] [Related]
3. Cytomegalovirus infections in lung and hematopoietic cell transplant recipients in the Organ Transplant Infection Prevention and Detection Study: A multi-year, multicenter prospective cohort study.
Avery RK; Silveira FP; Benedict K; Cleveland AA; Kauffman CA; Schuster MG; Dubberke ER; Husain S; Paterson DL; Chiller T; Pappas P
Transpl Infect Dis; 2018 Jun; 20(3):e12877. PubMed ID: 29512935
[TBL] [Abstract][Full Text] [Related]
4. Mortality in recipients of allogeneic haematopoietic cell transplantation in the era of cytomegalovirus primary prophylaxis: a single-centre retrospective experience.
Febres-Aldana A; Khawaja F; Morado-Aramburo O; Shigle TL; Rondon G; Sassine J; Spallone A; Srinivasan K; Ramdial J; Alousi A; Champlin R; Chen G; Daher M; Rezvani K; Ariza-Heredia EJ; Shpall EJ; Chemaly RF
Clin Microbiol Infect; 2024 Jun; 30(6):803-809. PubMed ID: 38460821
[TBL] [Abstract][Full Text] [Related]
5. Efficiency and risk factors for CMV transmission in seronegative hematopoietic stem cell recipients.
Pergam SA; Xie H; Sandhu R; Pollack M; Smith J; Stevens-Ayers T; Ilieva V; Kimball LE; Huang ML; Hayes TS; Corey L; Boeckh MJ
Biol Blood Marrow Transplant; 2012 Sep; 18(9):1391-1400. PubMed ID: 22387334
[TBL] [Abstract][Full Text] [Related]
6. Effect of Sirolimus Exposure on the Need for Preemptive Antiviral Therapy for Cytomeglovirus Infection after Allogeneic Hematopoietic Stem Cell Transplantation.
Guglieri-Lopez B; Perez-Pitarch A; Garcia-Cadenas I; Gimenez E; Barba P; Rabella N; Hernandez-Boluda JC; Fox L; Valcarcel D; Esquirol A; Ferriols-Lisart R; Sierra J; Solano C; Navarro D; Martino R; Piñana JL
Biol Blood Marrow Transplant; 2019 May; 25(5):1022-1030. PubMed ID: 30639821
[TBL] [Abstract][Full Text] [Related]
7. Cytomegalovirus Infection after CD34(+)-Selected Hematopoietic Cell Transplantation.
Huang YT; Neofytos D; Foldi J; Kim SJ; Maloy M; Chung D; Castro-Malaspina H; Giralt SA; Papadopoulos E; Perales MA; Jakubowski AA; Papanicolaou GA
Biol Blood Marrow Transplant; 2016 Aug; 22(8):1480-1486. PubMed ID: 27178374
[TBL] [Abstract][Full Text] [Related]
8. Mixed vs full donor engraftment early after hematopoietic cell transplant: Impact on incidence and control of cytomegalovirus infection.
Green JS; Shanley RM; Brunstein CG; Young JH; Verneris MR
Transpl Infect Dis; 2019 Jun; 21(3):e13070. PubMed ID: 30864271
[TBL] [Abstract][Full Text] [Related]
9. Incidence, risk factors, and outcome of cytomegalovirus viremia and gastroenteritis in patients with gastrointestinal graft-versus-host disease.
Bhutani D; Dyson G; Manasa R; Deol A; Ratanatharathorn V; Ayash L; Abidi M; Lum LG; Al-Kadhimi Z; Uberti JP
Biol Blood Marrow Transplant; 2015 Jan; 21(1):159-64. PubMed ID: 25445637
[TBL] [Abstract][Full Text] [Related]
10. Cytomegalovirus reactivation is associated with an increased risk of late-onset invasive aspergillosis independently of grade II-IV acute graft-versus-host disease in allogeneic hematopoietic stem cell transplantation: JSTCT Transplant Complications Working Group.
Kimura SI; Tamaki M; Okinaka K; Seo S; Uchida N; Igarashi A; Ozawa Y; Ikegame K; Eto T; Tanaka M; Shiratori S; Nakamae H; Sawa M; Kawakita T; Onizuka M; Fukuda T; Atsuta Y; Kanda Y; Nakasone H
Ann Hematol; 2021 Dec; 100(12):3029-3038. PubMed ID: 34490500
[TBL] [Abstract][Full Text] [Related]
11. Pre-transplant cytomegalovirus (CMV) serostatus remains the most important determinant of CMV reactivation after allogeneic hematopoietic stem cell transplantation in the era of surveillance and preemptive therapy.
George B; Pati N; Gilroy N; Ratnamohan M; Huang G; Kerridge I; Hertzberg M; Gottlieb D; Bradstock K
Transpl Infect Dis; 2010 Aug; 12(4):322-9. PubMed ID: 20487414
[TBL] [Abstract][Full Text] [Related]
12. Cytomegalovirus Infection in Pediatric Hematopoietic Stem Cell Transplantation: Risk Factors for Primary Infection and Cases of Recurrent and Late Infection at a Single Center.
Rowe RG; Guo D; Lee M; Margossian S; London WB; Lehmann L
Biol Blood Marrow Transplant; 2016 Jul; 22(7):1275-1283. PubMed ID: 27090959
[TBL] [Abstract][Full Text] [Related]
13. Cytomegalovirus Reactivations in Allogeneic Hematopoietic Stem Cell Transplantation from HLA-Matched and Haploidentical Donors with Post-Transplantation Cyclophosphamide.
Chorão P; Henriques M; Villalba M; Montoro J; Balaguer-Roselló A; González EM; Gómez MD; Gómez I; Solves P; Santiago M; Asensi P; Lamas B; Bataller A; Granados P; Eiris J; Martínez D; Louro A; Rebollar P; Perla A; Salavert M; de la Rubia J; Sanz MÁ; Sanz J
Transplant Cell Ther; 2024 May; 30(5):538.e1-538.e10. PubMed ID: 38331195
[TBL] [Abstract][Full Text] [Related]
14. Cytomegalovirus infection after allogeneic transplantation: comparison of cord blood with peripheral blood and marrow graft sources.
Walker CM; van Burik JA; De For TE; Weisdorf DJ
Biol Blood Marrow Transplant; 2007 Sep; 13(9):1106-15. PubMed ID: 17697973
[TBL] [Abstract][Full Text] [Related]
15. Cytomegalovirus in hematopoietic stem cell transplant recipients: Current status, known challenges, and future strategies.
Boeckh M; Nichols WG; Papanicolaou G; Rubin R; Wingard JR; Zaia J
Biol Blood Marrow Transplant; 2003 Sep; 9(9):543-58. PubMed ID: 14506657
[TBL] [Abstract][Full Text] [Related]
16. Dynamics of cytomegalovirus-specific T-cell recovery in allogeneic hematopoietic cell transplant recipients using a commercially available flow cytometry assay: A pilot study.
Jacobs SE; Ibrahim U; Vega AB; Lagdameo J; Callahan J; Govindarajulu U; Gitman M; Levine JE; Rana M; Keyzner A
Transpl Infect Dis; 2024 Jun; 26(3):e14290. PubMed ID: 38708941
[TBL] [Abstract][Full Text] [Related]
17. Letermovir for primary and secondary cytomegalovirus prevention in allogeneic hematopoietic cell transplant recipients: Real-world experience.
Lin A; Maloy M; Su Y; Bhatt V; DeRespiris L; Griffin M; Lau C; Proli A; Barker J; Shaffer B; Giralt SA; Jakubowski AA; Papadopoulos EB; Papanicolaou GA; Seo SK; Perales MA
Transpl Infect Dis; 2019 Dec; 21(6):e13187. PubMed ID: 31585500
[TBL] [Abstract][Full Text] [Related]
18. Insufficient Antigen Presentation Due to Viral Immune Evasion Explains Lethal Cytomegalovirus Organ Disease After Allogeneic Hematopoietic Cell Transplantation.
Holtappels R; Schader SI; Oettel O; Podlech J; Seckert CK; Reddehase MJ; Lemmermann NAW
Front Cell Infect Microbiol; 2020; 10():157. PubMed ID: 32351904
[TBL] [Abstract][Full Text] [Related]
19. Real world experience: Examining outcomes using letermovir for CMV prophylaxis in high-risk allogeneic hematopoietic stem cell patients in the setting of using T-cell depletion as GVHD prophylaxis.
Dwabe S; Hsiao M; Ali A; Rodman J; Savitala-Damerla L; Nazaretyan S; Kimberly Schiff NP; Tam E; Ladha A; Woan K; Chaudhary P; Yaghmour G
Transpl Immunol; 2023 Feb; 76():101769. PubMed ID: 36464218
[TBL] [Abstract][Full Text] [Related]
20. Deleterious Effect of Steroids on Cytomegalovirus Infection Rate after Allogeneic Stem Cell Transplantation Depends on Pretransplant Cytomegalovirus Serostatus of Donors and Recipients.
Suárez-Lledó M; Martínez-Cibrián N; Gutiérrez-García G; Dimova-Svetoslavova V; Marcos MA; Martín-Antonio B; Martínez-Trillos A; Villamor N; Rosiñol L; Martínez C; Fernández-Avilés F; García-Vidal C; Urbano-Ispizua Á; Rovira M
Biol Blood Marrow Transplant; 2018 Oct; 24(10):2088-2093. PubMed ID: 29753162
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
